Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 17;23(1):98.
doi: 10.1186/s12879-023-08071-9.

Injectable long acting antiretroviral for HIV treatment and prevention: perspectives of potential users

Laurence Slama  1   2 , Raphael Porcher  3   4 , Françoise Linard  5   6 , Catherine Chakvetadze  7 , Agnès Cros  5   8 , Séverine Carillon  9 , Lucille Gallardo  5   10 , Jean-Paul Viard  5   11 , Jean-Michel Molina  12   13
Affiliations

Injectable long acting antiretroviral for HIV treatment and prevention: perspectives of potential users

Laurence Slama et al. BMC Infect Dis. .

Abstract

Background: The use of long acting injectable (LAA) antiretroviral drugs may be an alternative option for HIV treatment and prevention. Our study focused on patient perspectives to understand which individuals, among people with HIV (PWH) and pre-exposure prophylaxis (PrEP) users, would constitute the preferential target for such treatments in terms of expectations, tolerability, adherence and quality of life.

Methods: The study consisted in one self-administrated questionnaire. Data collected included lifestyle issues, medical history, perceived benefits and inconveniences of LAA. Groups were compared using Wilcoxon rank tests or Fisher's exact test.

Results: In 2018, 100 PWH and 100 PrEP users were enrolled. Overall, 74% of PWH and 89% of PrEP users expressed interest for LAA with a significantly higher rate for PrEP users (p = 0.001). No characteristics were associated with acceptance of LAA in both groups in term of demographics, lifestyle or comorbidities.

Conclusion: PWH and PrEP users expressed a high level of interest in LAA, since a large majority seems to be in favor of this new approach. Further studies should be conducted to better characterize targeted individuals.

Keywords: HIV prevention; HIV treatment; Long-acting cART; PrEP; Quantitative study.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential competing with respect to the research authorship and publication of this article.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Saag MS, Gandhi RT, Hoy JF, Landovitz RJ, Thompson MA, Sax PE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society-USA panel. JAMA. 2020;324(16):1651–1669. doi: 10.1001/jama.2020.17025. - DOI - PMC - PubMed
    1. Schaefer R, Schmidt HA, Ravasi G, Mozalevskis A, Rewari BB, Lule F, et al. Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study. Lancet HIV. 2021;8(8):e502–e510. doi: 10.1016/S2352-3018(21)00127-2. - DOI - PMC - PubMed
    1. Gakhar H, Kamali A, Holodniy M. Health-related quality of life assessment after antiretroviral therapy: a review of the literature. Drugs. 2013;73(7):651–672. doi: 10.1007/s40265-013-0040-4. - DOI - PMC - PubMed
    1. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/15/v.... Accessed 10 Sept 2021. USDoHaHSGftUoAAiAaAwHAa.
    1. Boffito M, Jackson A, Owen A, Becker S. New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents. Drugs. 2014;74(1):7–13. doi: 10.1007/s40265-013-0163-7. - DOI - PubMed